New indication for telportin approved in China

2025-07-03 15:50:22

Eli Lilly announced that Mufengda (tilpoxetine injection) has been approved by the China National Medical Products Administration (NMPA) as the first and currently the only prescription drug for the treatment of moderate to severe obstructive sleep apnea (OSA) in obese adult patients. Tipoxetine can improve sleep disorders in obese adult patients with moderate to severe obstructive sleep apnea. The use of this indication requires control of diet and increased exercise.

Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    South Korean Ministry of Foreign Affairs: U.S. Secretary of State Rubio and South Korean and Japanese diplomats agreed to strengthen cooperation in areas such as energy, shipbuilding, and supply chain security (including critical minerals and artificial intelligence).
                            2025-07-11

                                    A South Korean transport ministry spokesman said it was preparing to order all airlines operating Boeing (BA.N) aircraft to check fuel taps in accordance with a 2018 notice from the U.S. Federal Aviation Administration (FAA).
                            2025-07-14

                                    Market news: Apple (AAPL.O) plans to launch new MacBook Pro, iPhone 17E and iPad in early 2026.
                            2025-07-11

                                    Shanghai: The scale of the city's artificial intelligence industry exceeded 118 billion yuan in the first quarter of this year
                            2025-07-10

                                    Bitcoin rises by more than $1,000 in the short term
                            2025-07-14